New drug duo aims to shrink tough head and neck tumors
NCT ID NCT06332092
First seen Mar 20, 2026 · Last updated Jun 12, 2026 · Updated 16 times
Summary
This study tests two different doses of the experimental drug FID-007 combined with cetuximab in people with advanced head and neck cancer that has come back or spread. About 46 adults whose cancer worsened after immunotherapy will be randomly assigned to one of two dosing schedules. The main goal is to see how well the combination shrinks tumors and to check for side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Fort Wayne Medical Oncology and Hematology
Fort Wayne, Indiana, 46804, United States
-
Highlands Oncology - North Hills
Fayetteville, Arkansas, 72703, United States
-
Moffitt Cancer Center Magnolia Campus
Tampa, Florida, 33612, United States
-
Texas Oncology - Baylor Charles A. Sammons Cancer Center
Dallas, Texas, 75246, United States
-
Texas Oncology - Northeast Texas Cancer & Research Institute
Tyler, Texas, 75702, United States
-
USC/Norris Comprehensive Cancer Center and Hospital
Los Angeles, California, 90033, United States
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.